Press Releases

Philogen publishes a new study on OncoFAP in Clinical Cancer Research

The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs...

Philogen announces publication of IL12-7NP2 (an Interleukin-12 fusion protein against Fibroblast Activation Protein) in Journal for Immunotherapy of Cancer.

The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to...

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)